Group

🧬 RNAi Technology: Revolutionizing Gene Silencing

RNA interference (RNAi) is a biological process where RNA molecules inhibit gene expression by neutralizing targeted mRNA molecules. Since its discovery, RNAi has become a powerful tool for genetic research and therapy.

🧪 What Is RNAi?

RNAi involves:

• Small interfering RNA (siRNA) or

• MicroRNA (miRNA)binding to complementary mRNA sequences, leading to their degradation or suppression, effectively silencing specific genes.

💡 Applications

1. Therapeutics

• Treating diseases by silencing harmful genes

• Applications in cancer, viral infections, neurodegenerative disorders, and rare genetic diseases

• Example: Patisiran, the first FDA-approved RNAi drug (for hereditary ATTR amyloidosis)

1. Drug Discovery

• High-throughput screening to identify gene targets

1. Agricultural Biotechnology

• Pest-resistant crops through gene silencing

• Viral protection in plants

1. Functional Genomics

• Studying gene function by "turning off" specific genes

📈 Market Outlook

• 2024 Market Size Estimate: ~$1.5–2 billion

• Projected CAGR (2024–2032): 12–15%

• Growth Factors:

• Increase in rare disease research

• Rise in precision medicine

• Advancements in delivery systems like lipid nanoparticles (LNPs)

🔬 Challenges

• ⚠️ Delivery mechanisms: Ensuring RNA molecules reach target tissues without degradation

• 🧠 Off-target effects and safety concerns

• 💰 High production costs

🏢 Key Companies

• Alnylam Pharmaceuticals

• Arrowhead Pharmaceuticals

• Dicerna Pharmaceuticals (acquired by Novo Nordisk)

• Silence Therapeutics

• Sirnaomics